Vascular and Endovascular Surgery

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

http://mc.manuscriptcentral.com/ves

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pierre-Paul, D.
Right arrow Articles by Gahtan, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pierre-Paul, D.
Right arrow Articles by Gahtan, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Vascular and Endovascular Surgery, Vol. 37, No. 5, 301-313 (2003)
DOI: 10.1177/153857440303700501

Reviews

Noncholesterol-Lowering Effects of Statins

Daphne Pierre-Paul, MD

Yale University School of Medicine, Section of Vascular Surgery, New Haven, CT

Vivian Gahtan, MD

Yale University School of Medicine, Section of Vascular Surgery, P.O. Box 208062, FMB 137, 333 Cedar Street, New Haven, CT 06520 Vivian.gahtan{at}yale.edu

Statins, 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, inhibit the rate-limiting enzyme in cholesterol synthesis and lead to a significant reduction of plasma lipid concentrations. As a clear correlation exists between serum cholesterol and cardiovascular risk, statins have become increasingly important in current preventive medicine. Studies prompted by the extraordinary benefits afforded by these drugs have reported minimal changes in the vasculature of hypercholesterolemic patients when compared with clinical benefits and have led to further investigations to determine the underlying reasons for these clinical benefits. The purpose of this review is to present the wide array of systems that HMGCoA reductase inhibitors are known to influence, which range from adverse events due to coronary artery disease, stroke risk, platelet function, endothelial function, and inflammatory effects to intracellular signaling pathways that control vascular cell migration, proliferation, and differentiation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
V. M. Campese and J. Park
HMG-CoA Reductase Inhibitors and Renal Function
Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1100 - 1103.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Sugita, H. Sugita, and M. Kaneki
Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1390 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
N. D. Vaziri
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
Am J Physiol Renal Physiol, February 1, 2006; 290(2): F262 - F272.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
V. M. Campese, M. K. Nadim, and M. Epstein
Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17.
[Abstract] [Full Text] [PDF]